מכפיל P/S עתידי: Aethlon Medical, Inc. (AEMD)

Aethlon Medical (AEMD) is striving to optimize its global filter distribution networks to maintain high margins. The forward price-to-sales ratio on the GURU.Markets chart demonstrates progress toward this goal, with the metric holding at 9.60. However, geopolitical sanctions and the clinical trial stage of the Hemopurifier for oncology treatment create certain obstacles to rapid business scaling.

To build a defensive portfolio, fundamental screening requires an analysis of the market capitalization to expected revenue ratio, which allows for the valuation of future cash flows. Since Aethlon Medical (AEMD) is in the clinical testing stage without pricing power, the forward price-to-sales ratio reflects the market's speculative expectations regarding the commercial success of the equipment.